Author:
Narang Jagriti,Malhotra Nitesh,Singh Gajendra,Pundir C. S.
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Bioengineering,Biotechnology
Reference30 articles.
1. Cohen MS, Hellmann N, Levy JA, DeCock K, Lange (2008) The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 118:1244
2. Grady RW, Giardina PJ (2000) Iron chelation: rationale for combination therapy. In: Dadman DG, Bergeron RJ, Brittenham GM (eds) Iron Chelators: new development strategies. Ponte VedraBeach, Saratoga, p 293
3. Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A (2004) The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 11:2161
4. Kontoghiorghes GJ, Barlett AN, Hoffbrand AV (1990) Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) I. iron chelation and metabolic studies. Br J Haematol 76:301
5. Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ (1992) Efficacy and possible adverse effects of the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 80:593
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献